| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030599240 |
| P356 | DOI | 10.1007/S00705-003-0006-Z |
| P953 | full work available at URL | http://link.springer.com/content/pdf/10.1007/s00705-003-0006-z |
| https://link.springer.com/article/10.1007/s00705-003-0006-z/fulltext.html | ||
| https://link.springer.com/content/pdf/10.1007/s00705-003-0006-z.pdf | ||
| P698 | PubMed publication ID | 12721793 |
| P5875 | ResearchGate publication ID | 10781637 |
| P50 | author | Mariano Esteban | Q30004051 |
| P2093 | author name string | Finke D | |
| Kraehenbuhl JP | |||
| Acha-Orbea H | |||
| Ramirez JC | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Vaccinia virus | Q1986297 |
| P304 | page(s) | 827-839 | |
| P577 | publication date | 2003-05-01 | |
| P1433 | published in | Archives of Virology | Q2860564 |
| P1476 | title | Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration | |
| P478 | volume | 148 |
| Q35628697 | A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations |
| Q30384745 | Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. |
| Q36883057 | Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic |
| Q45423126 | Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help |
| Q80445239 | Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses |
| Q44100720 | Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice |
| Q27008256 | Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination |
| Q36194078 | Carriers for the delivery of a vaccine against respiratory syncytial virus |
| Q38156198 | Clinical applications of attenuated MVA poxvirus strain. |
| Q36488676 | Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines |
| Q28258417 | Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases |
| Q33635050 | Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice |
| Q37596422 | Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting |
| Q35904455 | Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development |
| Q37590335 | Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity |
| Q37358213 | Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge |
| Q35256115 | Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitis. |
| Q34017475 | In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate |
| Q38619090 | Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. |
| Q35575565 | Non-equilibrium and differential function between intraepithelial and lamina propria virus-specific TCRalphabeta(+) CD8alphabeta(+) T cells in the small intestinal mucosa |
| Q39756926 | Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes |
| Q40384316 | Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery. |
| Q64052778 | Skin immunisation activates an innate lymphoid cell-monocyte axis regulating CD8 effector recruitment to mucosal tissues |
| Q34780607 | Smallpox vaccines: targets of protective immunity |
| Q92406222 | The Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice |
| Q90646281 | The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo |
| Q54435315 | The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice. |
| Q34026061 | Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses |
| Q51989059 | Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. |
Search more.